
MelliCell is developing novel therapeutics for metabolic and neurological conditions, supported by its M³ human fat-cell engineering platform. Its research aims to identify drug targets and improve preclinical models for diseases including obesity and certain neurodevelopmental disorders. The company has reported encouraging preclinical results for an oral drug candidate and is preparing for clinical testing; human treatment benefits are not yet established.
MelliCell hasn't reviewed it yet. Once they claim the page, every detail here is theirs to correct.
MelliCell hasn't claimed this page yet. Kindr doesn't accept donations for an organization until it has claimed its page and confirmed the details.
Comments
Log in to comment
Join the conversation with a Kindr account — creating one takes a minute.